Global Gynecological Cancer Drugs Market
Global Gynecological Cancer Drugs Market

Gynecological Cancer Drugs Comprehensive Study by Type (Uterine Cancer, Ovarian Cancer, Vaginal Cancer, Vulvar Cancer, Cervical Cancer), Application (Hospital, Clinic, Other), Physical Examination (Biopsy, Blood tests, Human Chorionic Gonadotropin (hCG) test, Ultrasound, MRI (Magnetic resonance imaging), PET (Positron emission tomography), CT scans), Stage (Stage I Cancer, Stage II Cancer, Stage III Cancer, Stage IV Cancer) Players and Region - Global Market Outlook to 2026

Gynecological Cancer Drugs Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Feb 2021 Edition 229 Pages 216 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global Gynecological Cancer Drugs Market Overview:
Gynecologic cancer is any cancer that starts in a woman's reproductive organs. Five main types of cancer affect a woman's reproductive organs are cervical, ovarian, uterine, vaginal, and vulvar. As a group, they are referred to as gynecologic cancer. The sixth type of gynecologic cancer is a very rare fallopian tube cancer. Rapid innovations in devices and technological advancement have encouraged doctors and researchers to shift their focus from traditional diagnostic methods to personalized medicines. To treat and prevent the disease, gynecological cancer drugs are produced. These drugs are used for pre malignant lesions, early invasive stage and advanced invasive stage. Also, there are various types of treatment available which uses these drugs. Hence, there is a high demand which will propel the growth of the market.

Growth Drivers
  • The Rising Occurrence of Various Types of Gynecologic Cancer Including Uterine Cancer, Ovarian Cancer, Vaginal Cancer, Vulvar Cancer
  • Surging Investment on Research and Development in Gynecology

Market Trends
  • Advancements in Treatment of Gynecologic Cancer
  • Increasing Approval of New Drugs

Roadblocks
  • Patent Expiry of Various Major Drugs

Opportunities
  • Enhancement in Healthcare Expenditure in Developed Regions
  • Huge Technological Advancements in Diagnostics Devices

Challenges
  • Lack of Proper Reimbursement Policies in the Developing Countries


Competitive Landscape:
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.
Some of the key players profiled in the report are Thermo Fisher Scientific (United States), Siemens Healthcare GmbH (Germany), Merck & Company, Inc. (United States), Novartis AG (Switzerland), Pfizer, Inc. (United States), Bio-Rad Technologies Inc. (United States), Abbott (United States), GlaxoSmithKline plc (United Kingdom), F. Hoffmann-La Roche Ltd. (Switzerland) and Becton, Dickinson and Company (United States). Additionally, following companies can also be profiled that are part of our coverage like Eli Lilly and Company (United States), Bristol Myers Squibb Co. (United States) and Quest Diagnostics Incorporated. (United States). Analyst at AMA Research see United States Players to retain maximum share of Global Gynecological Cancer Drugs market by 2026. Considering Market by Physical Examination, the sub-segment i.e. Biopsy will boost the Gynecological Cancer Drugs market. Considering Market by Stage, the sub-segment i.e. Stage I Cancer will boost the Gynecological Cancer Drugs market.

Latest Market Insights:
On 25th February 2019, Roche has entered into an agreement to acquire Spark therapeutics. This acquisition will offer new opportunities of treatment of serious diseases.

In June 2020, Genelux Corporation, a privately-held, clinical-stage immuno-oncology company, announced that it has formed a Clinical Advisory Board (CAB) on gynecologic cancers that will guide the clinical development of its lead clinical-stage candidate, Olvi-Vec.

In Sept 2020, Cancer patient advocates and medical professionals in more than 20 countries are planning activities for World Gynecologic Oncology Day (World GO Day).

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be provided prior to purchase

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Gynecological Cancer Drugs market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Gynecological Cancer Drugs market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Venture Capitalists and Private Equity Firms, New Entrants/Investors, Analyst and Strategic Business Planners, Gynecologic Cancer Diagnostics Devices and Drugs Manufacturers, Suppliers, and Distributors, Key Raw Material Manufacturers, Government Regulatory and Research Organizations and End-Use Industries.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.
Report Objectives / Segmentation Covered
By Type
  • Uterine Cancer
  • Ovarian Cancer
  • Vaginal Cancer
  • Vulvar Cancer
  • Cervical Cancer
By Application
  • Hospital
  • Clinic
  • Other
By Physical Examination
  • Biopsy
  • Blood tests
  • Human Chorionic Gonadotropin (hCG) test
  • Ultrasound
  • MRI (Magnetic resonance imaging)
  • PET (Positron emission tomography)
  • CT scans

By Stage
  • Stage I Cancer
  • Stage II Cancer
  • Stage III Cancer
  • Stage IV Cancer

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. The Rising Occurrence of Various Types of Gynecologic Cancer Including Uterine Cancer, Ovarian Cancer, Vaginal Cancer, Vulvar Cancer
      • 3.2.2. Surging Investment on Research and Development in Gynecology
    • 3.3. Market Challenges
      • 3.3.1. Lack of Proper Reimbursement Policies in the Developing Countries
    • 3.4. Market Trends
      • 3.4.1. Advancements in Treatment of Gynecologic Cancer
      • 3.4.2. Increasing Approval of New Drugs
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Gynecological Cancer Drugs, by Type, Application, Physical Examination, Stage and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Gynecological Cancer Drugs (Value)
      • 5.2.1. Global Gynecological Cancer Drugs by: Type (Value)
        • 5.2.1.1. Uterine Cancer
        • 5.2.1.2. Ovarian Cancer
        • 5.2.1.3. Vaginal Cancer
        • 5.2.1.4. Vulvar Cancer
        • 5.2.1.5. Cervical Cancer
      • 5.2.2. Global Gynecological Cancer Drugs by: Application (Value)
        • 5.2.2.1. Hospital
        • 5.2.2.2. Clinic
        • 5.2.2.3. Other
      • 5.2.3. Global Gynecological Cancer Drugs by: Physical Examination (Value)
        • 5.2.3.1. Biopsy
        • 5.2.3.2. Blood tests
        • 5.2.3.3. Human Chorionic Gonadotropin (hCG) test
        • 5.2.3.4. Ultrasound
        • 5.2.3.5. MRI (Magnetic resonance imaging)
        • 5.2.3.6. PET (Positron emission tomography)
        • 5.2.3.7. CT scans
      • 5.2.4. Global Gynecological Cancer Drugs by: Stage (Value)
        • 5.2.4.1. Stage I Cancer
        • 5.2.4.2. Stage II Cancer
        • 5.2.4.3. Stage III Cancer
        • 5.2.4.4. Stage IV Cancer
      • 5.2.5. Global Gynecological Cancer Drugs Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Gynecological Cancer Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Thermo Fisher Scientific (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Siemens Healthcare GmbH (Germany)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Merck & Company, Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Novartis AG (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Pfizer, Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Bio-Rad Technologies Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Abbott (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. GlaxoSmithKline plc (United Kingdom)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. F. Hoffmann-La Roche Ltd. (Switzerland)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Becton, Dickinson and Company (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Gynecological Cancer Drugs Sale, by Type, Application, Physical Examination, Stage and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Gynecological Cancer Drugs (Value)
      • 7.2.1. Global Gynecological Cancer Drugs by: Type (Value)
        • 7.2.1.1. Uterine Cancer
        • 7.2.1.2. Ovarian Cancer
        • 7.2.1.3. Vaginal Cancer
        • 7.2.1.4. Vulvar Cancer
        • 7.2.1.5. Cervical Cancer
      • 7.2.2. Global Gynecological Cancer Drugs by: Application (Value)
        • 7.2.2.1. Hospital
        • 7.2.2.2. Clinic
        • 7.2.2.3. Other
      • 7.2.3. Global Gynecological Cancer Drugs by: Physical Examination (Value)
        • 7.2.3.1. Biopsy
        • 7.2.3.2. Blood tests
        • 7.2.3.3. Human Chorionic Gonadotropin (hCG) test
        • 7.2.3.4. Ultrasound
        • 7.2.3.5. MRI (Magnetic resonance imaging)
        • 7.2.3.6. PET (Positron emission tomography)
        • 7.2.3.7. CT scans
      • 7.2.4. Global Gynecological Cancer Drugs by: Stage (Value)
        • 7.2.4.1. Stage I Cancer
        • 7.2.4.2. Stage II Cancer
        • 7.2.4.3. Stage III Cancer
        • 7.2.4.4. Stage IV Cancer
      • 7.2.5. Global Gynecological Cancer Drugs Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Gynecological Cancer Drugs: by Type(USD Million)
  • Table 2. Gynecological Cancer Drugs Uterine Cancer , by Region USD Million (2015-2020)
  • Table 3. Gynecological Cancer Drugs Ovarian Cancer , by Region USD Million (2015-2020)
  • Table 4. Gynecological Cancer Drugs Vaginal Cancer , by Region USD Million (2015-2020)
  • Table 5. Gynecological Cancer Drugs Vulvar Cancer , by Region USD Million (2015-2020)
  • Table 6. Gynecological Cancer Drugs Cervical Cancer , by Region USD Million (2015-2020)
  • Table 7. Gynecological Cancer Drugs: by Application(USD Million)
  • Table 8. Gynecological Cancer Drugs Hospital , by Region USD Million (2015-2020)
  • Table 9. Gynecological Cancer Drugs Clinic , by Region USD Million (2015-2020)
  • Table 10. Gynecological Cancer Drugs Other , by Region USD Million (2015-2020)
  • Table 11. Gynecological Cancer Drugs: by Physical Examination(USD Million)
  • Table 12. Gynecological Cancer Drugs Biopsy , by Region USD Million (2015-2020)
  • Table 13. Gynecological Cancer Drugs Blood tests , by Region USD Million (2015-2020)
  • Table 14. Gynecological Cancer Drugs Human Chorionic Gonadotropin (hCG) test , by Region USD Million (2015-2020)
  • Table 15. Gynecological Cancer Drugs Ultrasound , by Region USD Million (2015-2020)
  • Table 16. Gynecological Cancer Drugs MRI (Magnetic resonance imaging) , by Region USD Million (2015-2020)
  • Table 17. Gynecological Cancer Drugs PET (Positron emission tomography) , by Region USD Million (2015-2020)
  • Table 18. Gynecological Cancer Drugs CT scans , by Region USD Million (2015-2020)
  • Table 19. Gynecological Cancer Drugs: by Stage(USD Million)
  • Table 20. Gynecological Cancer Drugs Stage I Cancer , by Region USD Million (2015-2020)
  • Table 21. Gynecological Cancer Drugs Stage II Cancer , by Region USD Million (2015-2020)
  • Table 22. Gynecological Cancer Drugs Stage III Cancer , by Region USD Million (2015-2020)
  • Table 23. Gynecological Cancer Drugs Stage IV Cancer , by Region USD Million (2015-2020)
  • Table 24. South America Gynecological Cancer Drugs, by Country USD Million (2015-2020)
  • Table 25. South America Gynecological Cancer Drugs, by Type USD Million (2015-2020)
  • Table 26. South America Gynecological Cancer Drugs, by Application USD Million (2015-2020)
  • Table 27. South America Gynecological Cancer Drugs, by Physical Examination USD Million (2015-2020)
  • Table 28. South America Gynecological Cancer Drugs, by Stage USD Million (2015-2020)
  • Table 29. Brazil Gynecological Cancer Drugs, by Type USD Million (2015-2020)
  • Table 30. Brazil Gynecological Cancer Drugs, by Application USD Million (2015-2020)
  • Table 31. Brazil Gynecological Cancer Drugs, by Physical Examination USD Million (2015-2020)
  • Table 32. Brazil Gynecological Cancer Drugs, by Stage USD Million (2015-2020)
  • Table 33. Argentina Gynecological Cancer Drugs, by Type USD Million (2015-2020)
  • Table 34. Argentina Gynecological Cancer Drugs, by Application USD Million (2015-2020)
  • Table 35. Argentina Gynecological Cancer Drugs, by Physical Examination USD Million (2015-2020)
  • Table 36. Argentina Gynecological Cancer Drugs, by Stage USD Million (2015-2020)
  • Table 37. Rest of South America Gynecological Cancer Drugs, by Type USD Million (2015-2020)
  • Table 38. Rest of South America Gynecological Cancer Drugs, by Application USD Million (2015-2020)
  • Table 39. Rest of South America Gynecological Cancer Drugs, by Physical Examination USD Million (2015-2020)
  • Table 40. Rest of South America Gynecological Cancer Drugs, by Stage USD Million (2015-2020)
  • Table 41. Asia Pacific Gynecological Cancer Drugs, by Country USD Million (2015-2020)
  • Table 42. Asia Pacific Gynecological Cancer Drugs, by Type USD Million (2015-2020)
  • Table 43. Asia Pacific Gynecological Cancer Drugs, by Application USD Million (2015-2020)
  • Table 44. Asia Pacific Gynecological Cancer Drugs, by Physical Examination USD Million (2015-2020)
  • Table 45. Asia Pacific Gynecological Cancer Drugs, by Stage USD Million (2015-2020)
  • Table 46. China Gynecological Cancer Drugs, by Type USD Million (2015-2020)
  • Table 47. China Gynecological Cancer Drugs, by Application USD Million (2015-2020)
  • Table 48. China Gynecological Cancer Drugs, by Physical Examination USD Million (2015-2020)
  • Table 49. China Gynecological Cancer Drugs, by Stage USD Million (2015-2020)
  • Table 50. Japan Gynecological Cancer Drugs, by Type USD Million (2015-2020)
  • Table 51. Japan Gynecological Cancer Drugs, by Application USD Million (2015-2020)
  • Table 52. Japan Gynecological Cancer Drugs, by Physical Examination USD Million (2015-2020)
  • Table 53. Japan Gynecological Cancer Drugs, by Stage USD Million (2015-2020)
  • Table 54. India Gynecological Cancer Drugs, by Type USD Million (2015-2020)
  • Table 55. India Gynecological Cancer Drugs, by Application USD Million (2015-2020)
  • Table 56. India Gynecological Cancer Drugs, by Physical Examination USD Million (2015-2020)
  • Table 57. India Gynecological Cancer Drugs, by Stage USD Million (2015-2020)
  • Table 58. South Korea Gynecological Cancer Drugs, by Type USD Million (2015-2020)
  • Table 59. South Korea Gynecological Cancer Drugs, by Application USD Million (2015-2020)
  • Table 60. South Korea Gynecological Cancer Drugs, by Physical Examination USD Million (2015-2020)
  • Table 61. South Korea Gynecological Cancer Drugs, by Stage USD Million (2015-2020)
  • Table 62. Taiwan Gynecological Cancer Drugs, by Type USD Million (2015-2020)
  • Table 63. Taiwan Gynecological Cancer Drugs, by Application USD Million (2015-2020)
  • Table 64. Taiwan Gynecological Cancer Drugs, by Physical Examination USD Million (2015-2020)
  • Table 65. Taiwan Gynecological Cancer Drugs, by Stage USD Million (2015-2020)
  • Table 66. Australia Gynecological Cancer Drugs, by Type USD Million (2015-2020)
  • Table 67. Australia Gynecological Cancer Drugs, by Application USD Million (2015-2020)
  • Table 68. Australia Gynecological Cancer Drugs, by Physical Examination USD Million (2015-2020)
  • Table 69. Australia Gynecological Cancer Drugs, by Stage USD Million (2015-2020)
  • Table 70. Rest of Asia-Pacific Gynecological Cancer Drugs, by Type USD Million (2015-2020)
  • Table 71. Rest of Asia-Pacific Gynecological Cancer Drugs, by Application USD Million (2015-2020)
  • Table 72. Rest of Asia-Pacific Gynecological Cancer Drugs, by Physical Examination USD Million (2015-2020)
  • Table 73. Rest of Asia-Pacific Gynecological Cancer Drugs, by Stage USD Million (2015-2020)
  • Table 74. Europe Gynecological Cancer Drugs, by Country USD Million (2015-2020)
  • Table 75. Europe Gynecological Cancer Drugs, by Type USD Million (2015-2020)
  • Table 76. Europe Gynecological Cancer Drugs, by Application USD Million (2015-2020)
  • Table 77. Europe Gynecological Cancer Drugs, by Physical Examination USD Million (2015-2020)
  • Table 78. Europe Gynecological Cancer Drugs, by Stage USD Million (2015-2020)
  • Table 79. Germany Gynecological Cancer Drugs, by Type USD Million (2015-2020)
  • Table 80. Germany Gynecological Cancer Drugs, by Application USD Million (2015-2020)
  • Table 81. Germany Gynecological Cancer Drugs, by Physical Examination USD Million (2015-2020)
  • Table 82. Germany Gynecological Cancer Drugs, by Stage USD Million (2015-2020)
  • Table 83. France Gynecological Cancer Drugs, by Type USD Million (2015-2020)
  • Table 84. France Gynecological Cancer Drugs, by Application USD Million (2015-2020)
  • Table 85. France Gynecological Cancer Drugs, by Physical Examination USD Million (2015-2020)
  • Table 86. France Gynecological Cancer Drugs, by Stage USD Million (2015-2020)
  • Table 87. Italy Gynecological Cancer Drugs, by Type USD Million (2015-2020)
  • Table 88. Italy Gynecological Cancer Drugs, by Application USD Million (2015-2020)
  • Table 89. Italy Gynecological Cancer Drugs, by Physical Examination USD Million (2015-2020)
  • Table 90. Italy Gynecological Cancer Drugs, by Stage USD Million (2015-2020)
  • Table 91. United Kingdom Gynecological Cancer Drugs, by Type USD Million (2015-2020)
  • Table 92. United Kingdom Gynecological Cancer Drugs, by Application USD Million (2015-2020)
  • Table 93. United Kingdom Gynecological Cancer Drugs, by Physical Examination USD Million (2015-2020)
  • Table 94. United Kingdom Gynecological Cancer Drugs, by Stage USD Million (2015-2020)
  • Table 95. Netherlands Gynecological Cancer Drugs, by Type USD Million (2015-2020)
  • Table 96. Netherlands Gynecological Cancer Drugs, by Application USD Million (2015-2020)
  • Table 97. Netherlands Gynecological Cancer Drugs, by Physical Examination USD Million (2015-2020)
  • Table 98. Netherlands Gynecological Cancer Drugs, by Stage USD Million (2015-2020)
  • Table 99. Rest of Europe Gynecological Cancer Drugs, by Type USD Million (2015-2020)
  • Table 100. Rest of Europe Gynecological Cancer Drugs, by Application USD Million (2015-2020)
  • Table 101. Rest of Europe Gynecological Cancer Drugs, by Physical Examination USD Million (2015-2020)
  • Table 102. Rest of Europe Gynecological Cancer Drugs, by Stage USD Million (2015-2020)
  • Table 103. MEA Gynecological Cancer Drugs, by Country USD Million (2015-2020)
  • Table 104. MEA Gynecological Cancer Drugs, by Type USD Million (2015-2020)
  • Table 105. MEA Gynecological Cancer Drugs, by Application USD Million (2015-2020)
  • Table 106. MEA Gynecological Cancer Drugs, by Physical Examination USD Million (2015-2020)
  • Table 107. MEA Gynecological Cancer Drugs, by Stage USD Million (2015-2020)
  • Table 108. Middle East Gynecological Cancer Drugs, by Type USD Million (2015-2020)
  • Table 109. Middle East Gynecological Cancer Drugs, by Application USD Million (2015-2020)
  • Table 110. Middle East Gynecological Cancer Drugs, by Physical Examination USD Million (2015-2020)
  • Table 111. Middle East Gynecological Cancer Drugs, by Stage USD Million (2015-2020)
  • Table 112. Africa Gynecological Cancer Drugs, by Type USD Million (2015-2020)
  • Table 113. Africa Gynecological Cancer Drugs, by Application USD Million (2015-2020)
  • Table 114. Africa Gynecological Cancer Drugs, by Physical Examination USD Million (2015-2020)
  • Table 115. Africa Gynecological Cancer Drugs, by Stage USD Million (2015-2020)
  • Table 116. North America Gynecological Cancer Drugs, by Country USD Million (2015-2020)
  • Table 117. North America Gynecological Cancer Drugs, by Type USD Million (2015-2020)
  • Table 118. North America Gynecological Cancer Drugs, by Application USD Million (2015-2020)
  • Table 119. North America Gynecological Cancer Drugs, by Physical Examination USD Million (2015-2020)
  • Table 120. North America Gynecological Cancer Drugs, by Stage USD Million (2015-2020)
  • Table 121. United States Gynecological Cancer Drugs, by Type USD Million (2015-2020)
  • Table 122. United States Gynecological Cancer Drugs, by Application USD Million (2015-2020)
  • Table 123. United States Gynecological Cancer Drugs, by Physical Examination USD Million (2015-2020)
  • Table 124. United States Gynecological Cancer Drugs, by Stage USD Million (2015-2020)
  • Table 125. Canada Gynecological Cancer Drugs, by Type USD Million (2015-2020)
  • Table 126. Canada Gynecological Cancer Drugs, by Application USD Million (2015-2020)
  • Table 127. Canada Gynecological Cancer Drugs, by Physical Examination USD Million (2015-2020)
  • Table 128. Canada Gynecological Cancer Drugs, by Stage USD Million (2015-2020)
  • Table 129. Mexico Gynecological Cancer Drugs, by Type USD Million (2015-2020)
  • Table 130. Mexico Gynecological Cancer Drugs, by Application USD Million (2015-2020)
  • Table 131. Mexico Gynecological Cancer Drugs, by Physical Examination USD Million (2015-2020)
  • Table 132. Mexico Gynecological Cancer Drugs, by Stage USD Million (2015-2020)
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Company Basic Information, Sales Area and Its Competitors
  • Table 143. Gynecological Cancer Drugs: by Type(USD Million)
  • Table 144. Gynecological Cancer Drugs Uterine Cancer , by Region USD Million (2021-2026)
  • Table 145. Gynecological Cancer Drugs Ovarian Cancer , by Region USD Million (2021-2026)
  • Table 146. Gynecological Cancer Drugs Vaginal Cancer , by Region USD Million (2021-2026)
  • Table 147. Gynecological Cancer Drugs Vulvar Cancer , by Region USD Million (2021-2026)
  • Table 148. Gynecological Cancer Drugs Cervical Cancer , by Region USD Million (2021-2026)
  • Table 149. Gynecological Cancer Drugs: by Application(USD Million)
  • Table 150. Gynecological Cancer Drugs Hospital , by Region USD Million (2021-2026)
  • Table 151. Gynecological Cancer Drugs Clinic , by Region USD Million (2021-2026)
  • Table 152. Gynecological Cancer Drugs Other , by Region USD Million (2021-2026)
  • Table 153. Gynecological Cancer Drugs: by Physical Examination(USD Million)
  • Table 154. Gynecological Cancer Drugs Biopsy , by Region USD Million (2021-2026)
  • Table 155. Gynecological Cancer Drugs Blood tests , by Region USD Million (2021-2026)
  • Table 156. Gynecological Cancer Drugs Human Chorionic Gonadotropin (hCG) test , by Region USD Million (2021-2026)
  • Table 157. Gynecological Cancer Drugs Ultrasound , by Region USD Million (2021-2026)
  • Table 158. Gynecological Cancer Drugs MRI (Magnetic resonance imaging) , by Region USD Million (2021-2026)
  • Table 159. Gynecological Cancer Drugs PET (Positron emission tomography) , by Region USD Million (2021-2026)
  • Table 160. Gynecological Cancer Drugs CT scans , by Region USD Million (2021-2026)
  • Table 161. Gynecological Cancer Drugs: by Stage(USD Million)
  • Table 162. Gynecological Cancer Drugs Stage I Cancer , by Region USD Million (2021-2026)
  • Table 163. Gynecological Cancer Drugs Stage II Cancer , by Region USD Million (2021-2026)
  • Table 164. Gynecological Cancer Drugs Stage III Cancer , by Region USD Million (2021-2026)
  • Table 165. Gynecological Cancer Drugs Stage IV Cancer , by Region USD Million (2021-2026)
  • Table 166. South America Gynecological Cancer Drugs, by Country USD Million (2021-2026)
  • Table 167. South America Gynecological Cancer Drugs, by Type USD Million (2021-2026)
  • Table 168. South America Gynecological Cancer Drugs, by Application USD Million (2021-2026)
  • Table 169. South America Gynecological Cancer Drugs, by Physical Examination USD Million (2021-2026)
  • Table 170. South America Gynecological Cancer Drugs, by Stage USD Million (2021-2026)
  • Table 171. Brazil Gynecological Cancer Drugs, by Type USD Million (2021-2026)
  • Table 172. Brazil Gynecological Cancer Drugs, by Application USD Million (2021-2026)
  • Table 173. Brazil Gynecological Cancer Drugs, by Physical Examination USD Million (2021-2026)
  • Table 174. Brazil Gynecological Cancer Drugs, by Stage USD Million (2021-2026)
  • Table 175. Argentina Gynecological Cancer Drugs, by Type USD Million (2021-2026)
  • Table 176. Argentina Gynecological Cancer Drugs, by Application USD Million (2021-2026)
  • Table 177. Argentina Gynecological Cancer Drugs, by Physical Examination USD Million (2021-2026)
  • Table 178. Argentina Gynecological Cancer Drugs, by Stage USD Million (2021-2026)
  • Table 179. Rest of South America Gynecological Cancer Drugs, by Type USD Million (2021-2026)
  • Table 180. Rest of South America Gynecological Cancer Drugs, by Application USD Million (2021-2026)
  • Table 181. Rest of South America Gynecological Cancer Drugs, by Physical Examination USD Million (2021-2026)
  • Table 182. Rest of South America Gynecological Cancer Drugs, by Stage USD Million (2021-2026)
  • Table 183. Asia Pacific Gynecological Cancer Drugs, by Country USD Million (2021-2026)
  • Table 184. Asia Pacific Gynecological Cancer Drugs, by Type USD Million (2021-2026)
  • Table 185. Asia Pacific Gynecological Cancer Drugs, by Application USD Million (2021-2026)
  • Table 186. Asia Pacific Gynecological Cancer Drugs, by Physical Examination USD Million (2021-2026)
  • Table 187. Asia Pacific Gynecological Cancer Drugs, by Stage USD Million (2021-2026)
  • Table 188. China Gynecological Cancer Drugs, by Type USD Million (2021-2026)
  • Table 189. China Gynecological Cancer Drugs, by Application USD Million (2021-2026)
  • Table 190. China Gynecological Cancer Drugs, by Physical Examination USD Million (2021-2026)
  • Table 191. China Gynecological Cancer Drugs, by Stage USD Million (2021-2026)
  • Table 192. Japan Gynecological Cancer Drugs, by Type USD Million (2021-2026)
  • Table 193. Japan Gynecological Cancer Drugs, by Application USD Million (2021-2026)
  • Table 194. Japan Gynecological Cancer Drugs, by Physical Examination USD Million (2021-2026)
  • Table 195. Japan Gynecological Cancer Drugs, by Stage USD Million (2021-2026)
  • Table 196. India Gynecological Cancer Drugs, by Type USD Million (2021-2026)
  • Table 197. India Gynecological Cancer Drugs, by Application USD Million (2021-2026)
  • Table 198. India Gynecological Cancer Drugs, by Physical Examination USD Million (2021-2026)
  • Table 199. India Gynecological Cancer Drugs, by Stage USD Million (2021-2026)
  • Table 200. South Korea Gynecological Cancer Drugs, by Type USD Million (2021-2026)
  • Table 201. South Korea Gynecological Cancer Drugs, by Application USD Million (2021-2026)
  • Table 202. South Korea Gynecological Cancer Drugs, by Physical Examination USD Million (2021-2026)
  • Table 203. South Korea Gynecological Cancer Drugs, by Stage USD Million (2021-2026)
  • Table 204. Taiwan Gynecological Cancer Drugs, by Type USD Million (2021-2026)
  • Table 205. Taiwan Gynecological Cancer Drugs, by Application USD Million (2021-2026)
  • Table 206. Taiwan Gynecological Cancer Drugs, by Physical Examination USD Million (2021-2026)
  • Table 207. Taiwan Gynecological Cancer Drugs, by Stage USD Million (2021-2026)
  • Table 208. Australia Gynecological Cancer Drugs, by Type USD Million (2021-2026)
  • Table 209. Australia Gynecological Cancer Drugs, by Application USD Million (2021-2026)
  • Table 210. Australia Gynecological Cancer Drugs, by Physical Examination USD Million (2021-2026)
  • Table 211. Australia Gynecological Cancer Drugs, by Stage USD Million (2021-2026)
  • Table 212. Rest of Asia-Pacific Gynecological Cancer Drugs, by Type USD Million (2021-2026)
  • Table 213. Rest of Asia-Pacific Gynecological Cancer Drugs, by Application USD Million (2021-2026)
  • Table 214. Rest of Asia-Pacific Gynecological Cancer Drugs, by Physical Examination USD Million (2021-2026)
  • Table 215. Rest of Asia-Pacific Gynecological Cancer Drugs, by Stage USD Million (2021-2026)
  • Table 216. Europe Gynecological Cancer Drugs, by Country USD Million (2021-2026)
  • Table 217. Europe Gynecological Cancer Drugs, by Type USD Million (2021-2026)
  • Table 218. Europe Gynecological Cancer Drugs, by Application USD Million (2021-2026)
  • Table 219. Europe Gynecological Cancer Drugs, by Physical Examination USD Million (2021-2026)
  • Table 220. Europe Gynecological Cancer Drugs, by Stage USD Million (2021-2026)
  • Table 221. Germany Gynecological Cancer Drugs, by Type USD Million (2021-2026)
  • Table 222. Germany Gynecological Cancer Drugs, by Application USD Million (2021-2026)
  • Table 223. Germany Gynecological Cancer Drugs, by Physical Examination USD Million (2021-2026)
  • Table 224. Germany Gynecological Cancer Drugs, by Stage USD Million (2021-2026)
  • Table 225. France Gynecological Cancer Drugs, by Type USD Million (2021-2026)
  • Table 226. France Gynecological Cancer Drugs, by Application USD Million (2021-2026)
  • Table 227. France Gynecological Cancer Drugs, by Physical Examination USD Million (2021-2026)
  • Table 228. France Gynecological Cancer Drugs, by Stage USD Million (2021-2026)
  • Table 229. Italy Gynecological Cancer Drugs, by Type USD Million (2021-2026)
  • Table 230. Italy Gynecological Cancer Drugs, by Application USD Million (2021-2026)
  • Table 231. Italy Gynecological Cancer Drugs, by Physical Examination USD Million (2021-2026)
  • Table 232. Italy Gynecological Cancer Drugs, by Stage USD Million (2021-2026)
  • Table 233. United Kingdom Gynecological Cancer Drugs, by Type USD Million (2021-2026)
  • Table 234. United Kingdom Gynecological Cancer Drugs, by Application USD Million (2021-2026)
  • Table 235. United Kingdom Gynecological Cancer Drugs, by Physical Examination USD Million (2021-2026)
  • Table 236. United Kingdom Gynecological Cancer Drugs, by Stage USD Million (2021-2026)
  • Table 237. Netherlands Gynecological Cancer Drugs, by Type USD Million (2021-2026)
  • Table 238. Netherlands Gynecological Cancer Drugs, by Application USD Million (2021-2026)
  • Table 239. Netherlands Gynecological Cancer Drugs, by Physical Examination USD Million (2021-2026)
  • Table 240. Netherlands Gynecological Cancer Drugs, by Stage USD Million (2021-2026)
  • Table 241. Rest of Europe Gynecological Cancer Drugs, by Type USD Million (2021-2026)
  • Table 242. Rest of Europe Gynecological Cancer Drugs, by Application USD Million (2021-2026)
  • Table 243. Rest of Europe Gynecological Cancer Drugs, by Physical Examination USD Million (2021-2026)
  • Table 244. Rest of Europe Gynecological Cancer Drugs, by Stage USD Million (2021-2026)
  • Table 245. MEA Gynecological Cancer Drugs, by Country USD Million (2021-2026)
  • Table 246. MEA Gynecological Cancer Drugs, by Type USD Million (2021-2026)
  • Table 247. MEA Gynecological Cancer Drugs, by Application USD Million (2021-2026)
  • Table 248. MEA Gynecological Cancer Drugs, by Physical Examination USD Million (2021-2026)
  • Table 249. MEA Gynecological Cancer Drugs, by Stage USD Million (2021-2026)
  • Table 250. Middle East Gynecological Cancer Drugs, by Type USD Million (2021-2026)
  • Table 251. Middle East Gynecological Cancer Drugs, by Application USD Million (2021-2026)
  • Table 252. Middle East Gynecological Cancer Drugs, by Physical Examination USD Million (2021-2026)
  • Table 253. Middle East Gynecological Cancer Drugs, by Stage USD Million (2021-2026)
  • Table 254. Africa Gynecological Cancer Drugs, by Type USD Million (2021-2026)
  • Table 255. Africa Gynecological Cancer Drugs, by Application USD Million (2021-2026)
  • Table 256. Africa Gynecological Cancer Drugs, by Physical Examination USD Million (2021-2026)
  • Table 257. Africa Gynecological Cancer Drugs, by Stage USD Million (2021-2026)
  • Table 258. North America Gynecological Cancer Drugs, by Country USD Million (2021-2026)
  • Table 259. North America Gynecological Cancer Drugs, by Type USD Million (2021-2026)
  • Table 260. North America Gynecological Cancer Drugs, by Application USD Million (2021-2026)
  • Table 261. North America Gynecological Cancer Drugs, by Physical Examination USD Million (2021-2026)
  • Table 262. North America Gynecological Cancer Drugs, by Stage USD Million (2021-2026)
  • Table 263. United States Gynecological Cancer Drugs, by Type USD Million (2021-2026)
  • Table 264. United States Gynecological Cancer Drugs, by Application USD Million (2021-2026)
  • Table 265. United States Gynecological Cancer Drugs, by Physical Examination USD Million (2021-2026)
  • Table 266. United States Gynecological Cancer Drugs, by Stage USD Million (2021-2026)
  • Table 267. Canada Gynecological Cancer Drugs, by Type USD Million (2021-2026)
  • Table 268. Canada Gynecological Cancer Drugs, by Application USD Million (2021-2026)
  • Table 269. Canada Gynecological Cancer Drugs, by Physical Examination USD Million (2021-2026)
  • Table 270. Canada Gynecological Cancer Drugs, by Stage USD Million (2021-2026)
  • Table 271. Mexico Gynecological Cancer Drugs, by Type USD Million (2021-2026)
  • Table 272. Mexico Gynecological Cancer Drugs, by Application USD Million (2021-2026)
  • Table 273. Mexico Gynecological Cancer Drugs, by Physical Examination USD Million (2021-2026)
  • Table 274. Mexico Gynecological Cancer Drugs, by Stage USD Million (2021-2026)
  • Table 275. Research Programs/Design for This Report
  • Table 276. Key Data Information from Secondary Sources
  • Table 277. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Gynecological Cancer Drugs: by Type USD Million (2015-2020)
  • Figure 5. Global Gynecological Cancer Drugs: by Application USD Million (2015-2020)
  • Figure 6. Global Gynecological Cancer Drugs: by Physical Examination USD Million (2015-2020)
  • Figure 7. Global Gynecological Cancer Drugs: by Stage USD Million (2015-2020)
  • Figure 8. South America Gynecological Cancer Drugs Share (%), by Country
  • Figure 9. Asia Pacific Gynecological Cancer Drugs Share (%), by Country
  • Figure 10. Europe Gynecological Cancer Drugs Share (%), by Country
  • Figure 11. MEA Gynecological Cancer Drugs Share (%), by Country
  • Figure 12. North America Gynecological Cancer Drugs Share (%), by Country
  • Figure 13. Global Gynecological Cancer Drugs share by Players 2020 (%)
  • Figure 14. Global Gynecological Cancer Drugs share by Players (Top 3) 2020(%)
  • Figure 15. Global Gynecological Cancer Drugs share by Players (Top 5) 2020(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Thermo Fisher Scientific (United States) Revenue, Net Income and Gross profit
  • Figure 18. Thermo Fisher Scientific (United States) Revenue: by Geography 2020
  • Figure 19. Siemens Healthcare GmbH (Germany) Revenue, Net Income and Gross profit
  • Figure 20. Siemens Healthcare GmbH (Germany) Revenue: by Geography 2020
  • Figure 21. Merck & Company, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 22. Merck & Company, Inc. (United States) Revenue: by Geography 2020
  • Figure 23. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 24. Novartis AG (Switzerland) Revenue: by Geography 2020
  • Figure 25. Pfizer, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 26. Pfizer, Inc. (United States) Revenue: by Geography 2020
  • Figure 27. Bio-Rad Technologies Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Bio-Rad Technologies Inc. (United States) Revenue: by Geography 2020
  • Figure 29. Abbott (United States) Revenue, Net Income and Gross profit
  • Figure 30. Abbott (United States) Revenue: by Geography 2020
  • Figure 31. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 32. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2020
  • Figure 33. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 34. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue: by Geography 2020
  • Figure 35. Becton, Dickinson and Company (United States) Revenue, Net Income and Gross profit
  • Figure 36. Becton, Dickinson and Company (United States) Revenue: by Geography 2020
  • Figure 37. Global Gynecological Cancer Drugs: by Type USD Million (2021-2026)
  • Figure 38. Global Gynecological Cancer Drugs: by Application USD Million (2021-2026)
  • Figure 39. Global Gynecological Cancer Drugs: by Physical Examination USD Million (2021-2026)
  • Figure 40. Global Gynecological Cancer Drugs: by Stage USD Million (2021-2026)
  • Figure 41. South America Gynecological Cancer Drugs Share (%), by Country
  • Figure 42. Asia Pacific Gynecological Cancer Drugs Share (%), by Country
  • Figure 43. Europe Gynecological Cancer Drugs Share (%), by Country
  • Figure 44. MEA Gynecological Cancer Drugs Share (%), by Country
  • Figure 45. North America Gynecological Cancer Drugs Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Thermo Fisher Scientific (United States)
  • Siemens Healthcare GmbH (Germany)
  • Merck & Company, Inc. (United States)
  • Novartis AG (Switzerland)
  • Pfizer, Inc. (United States)
  • Bio-Rad Technologies Inc. (United States)
  • Abbott (United States)
  • GlaxoSmithKline plc (United Kingdom)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Becton, Dickinson and Company (United States)
Additional players considered in the study are as follows:
Eli Lilly and Company (United States) , Bristol Myers Squibb Co. (United States) , Quest Diagnostics Incorporated. (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation